Your browser doesn't support javascript.
loading
Assessment of tumor hypoxia in spontaneous canine tumors after treatment with OMX, a novel H-NOX oxygen carrier, with [18F]FMISO PET/CT.
Choen, Sangkyung; Kent, Michael S; Loucks, F Alexandra; Winger, Jonathan A; Zwingenberger, Allison L.
Afiliación
  • Choen S; Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, 1 Shields Ave, 2112 Tupper Hall, Davis, CA, 95616, USA.
  • Kent MS; Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, 1 Shields Ave, 2112 Tupper Hall, Davis, CA, 95616, USA.
  • Loucks FA; Omniox, Inc., San Francisco, CA, USA.
  • Winger JA; Omniox, Inc., San Francisco, CA, USA.
  • Zwingenberger AL; Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, 1 Shields Ave, 2112 Tupper Hall, Davis, CA, 95616, USA. azwingen@ucdavis.edu.
BMC Vet Res ; 20(1): 196, 2024 May 13.
Article en En | MEDLINE | ID: mdl-38741109
ABSTRACT

BACKGROUND:

Hypoxia is a detrimental factor in solid tumors, leading to aggressiveness and therapy resistance. OMX, a tunable oxygen carrier from the heme nitric oxide/oxygen-binding (H-NOX) protein family, has the potential to reduce tumor hypoxia. [18F]Fluoromisonidazole ([18F]FMISO) positron emission tomography (PET) is the most widely used and investigated method for non-invasive imaging of tumor hypoxia. In this study, we used [18F]FMISO PET/CT (computed tomography) to assess the effect of OMX on tumor hypoxia in spontaneous canine tumors.

RESULTS:

Thirteen canine patients with various tumors (n = 14) were randomly divided into blocks of two, with the treatment groups alternating between receiving intratumoral (IT) OMX injection (OMX IT group) and intravenous (IV) OMX injection (OMX IV group). Tumors were regarded as hypoxic if maximum tumor-to-muscle ratio (TMRmax) was greater than 1.4. In addition, hypoxic volume (HV) was defined as the region with tumor-to-muscle ratio greater than 1.4 on [18F]FMISO PET images. Hypoxia was detected in 6/7 tumors in the OMX IT group and 5/7 tumors in the OMX IV injection group. Although there was no significant difference in baseline hypoxia between the OMX IT and IV groups, the two groups showed different responses to OMX. In the OMX IV group, hypoxic tumors (n = 5) exhibited significant reductions in tumor hypoxia, as indicated by decreased TMRmax and HV in [18F]FMISO PET imaging after treatment. In contrast, hypoxic tumors in the OMX IT group (n = 6) displayed a significant increase in [18F]FMISO uptake and variable changes in TMRmax and HV.

CONCLUSIONS:

[18F]FMISO PET/CT imaging presents a promising non-invasive procedure for monitoring tumor hypoxia and assessing the efficacy of hypoxia-modulating therapies in canine patients. OMX has shown promising outcomes in reducing tumor hypoxia, especially when administered intravenously, as evident from reductions in both TMRmax and HV in [18F]FMISO PET imaging.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de los Perros / Tomografía Computarizada por Tomografía de Emisión de Positrones / Hipoxia Tumoral / Misonidazol / Neoplasias Límite: Animals Idioma: En Revista: BMC Vet Res Asunto de la revista: MEDICINA VETERINARIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de los Perros / Tomografía Computarizada por Tomografía de Emisión de Positrones / Hipoxia Tumoral / Misonidazol / Neoplasias Límite: Animals Idioma: En Revista: BMC Vet Res Asunto de la revista: MEDICINA VETERINARIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido